Medical University of South Carolina: Neoplasms trials

The registry lists 14 Neoplasms studies with Medical University of South Carolina as lead sponsor. 5 are open to participants now and 3 have results posted.

Phase 1 1Phase 2 3No phase 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Resistance Training and Creatine Supplementation for Head and Neck CancerNot yet recruitingNCT07838090Not applicable
• Brain Metastases in Greater Size - Hypofractionated Options Trial (BIGSHOT)RecruitingNCT07227610Phase 2
• Intraoperative Molecular Imaging Using ICG for Head and Neck TumorsRecruitingNCT07149207Phase 2
• Clinical Alternatives for Reducing Harm Using E-cigarettesEnrolling by invitationNCT07039292Not applicable
• IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)RecruitingNCT06582784Not applicable
• VIDeOS for Smoking CessationCompletedNCT06307496Not applicableResults posted
• Incisional Negative Pressure Wound Therapy for Preoperatively Irradiated Lower Extremity Soft Tissue Sarcoma WoundsCompletedNCT02638298Not applicableResults posted
• Allogeneic Hematopoietic Stem Cell Transplantation With Reduced Intensity Pre-transplant Conditioning for the Treatment of High-risk Hematological Malignancies (V3)TerminatedNCT01139164Phase 2Results posted
• Feasibility of a Technology-Based Intervention for Depression Referral Uptake in Cancer SurvivorsActive, not recruitingNCT07091968Not applicable
• Optimizing Care for Cancer Survivors With Depression: Project 3CompletedNCT06930729Not applicable
• Text -Based Depression Screening Among Cancer SurvivorsCompletedNCT06894849Not applicable
• Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer SurgeryActive, not recruitingNCT06451003Not applicable
• Circulating Tumor DNA As Liquid Biopsy in Patients with Stage IV Solid Tumors, a Feasibility Study At MUSC HCCCompletedNCT03302325
• Bortezomib and Celecoxib in Treating Patients With Advanced Solid TumorsCompletedNCT00290680Phase 1